Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
MRK filed a Form 144 indicating a proposed sale of 8,614 shares of common stock with an aggregate market value of $720,039.95.
The notice lists Morgan Stanley Smith Barney LLC as the broker, the NYSE as the exchange, and an approximate sale date of November 3, 2025. The shares were acquired through restricted stock vesting under a registered plan on multiple dates.
Shares outstanding were 2,497,783,211.
Merck & Co., Inc. (MRK) furnished an 8-K under Item 2.02, providing an earnings press release for the third quarter of 2025 as Exhibit 99.1 and additional supplemental materials as Exhibit 99.2. The company states this information is being furnished and is not deemed filed under Section 18 of the Exchange Act.
The filing also includes Exhibit 104 (Cover Page Interactive Data File). Merck’s common stock trades on the NYSE under MRK.
Christine E. Seidman, a director of Merck & Co., Inc. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 100 common shares and the acquisition of 96.8069 phantom stock units that correspond to 96.8069 underlying common shares at a reported price of $83.93 per share. After the reported transactions, the reporting person beneficially owned 18,775.7818 shares. The filing explains phantom stock units are to be settled 100% in cash upon the reporting person’s termination of service per the Plan for Deferred Payment of Directors’ Compensation, and that holdings include shares acquired via dividend reinvestment. The form was signed by an attorney-in-fact on 10/02/2025.
Thomas H. Glocer, a director of Merck & Co., Inc. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 5,100 shares of Merck common stock in the non-derivative section. In the derivative section, Mr. Glocer acquired 580.8412 phantom stock units on the same date; those units are to be settled 100% in cash upon his termination of service under the referenced deferred compensation plan. The phantom units represent 580.8412 underlying common shares with an indicated price of $83.93, and the report lists 105,645.8965 shares beneficially owned following the transactions. The form is signed by an attorney-in-fact for Mr. Glocer on 10/02/2025. The filing notes that holdings include shares acquired through dividend reinvestment.
Mary Ellen Coe, identified as a director of Merck & Co. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 10 shares of Merck common stock and the acquisition of 357.4407 phantom stock units, each unit representing one share. The phantom units are tied to 357.4407 shares with a reference price of $83.93. The report lists total beneficial ownership following the transactions as 28,684.663 shares. The phantom units are to be settled 100% in cash upon the reporting person's termination of service under the plan's distribution schedule. The filing also notes holdings include shares from dividend reinvestment.
Merck & Co., Inc. completed an underwritten public offering of new investment-grade debt across multiple maturities. The company issued $500,000,000 of Floating Rate Notes due 2027, $750,000,000 of 3.850% Notes due 2027, $750,000,000 of 4.150% Notes due 2030, $1,000,000,000 of 4.550% Notes due 2032, $1,750,000,000 of 4.950% Notes due 2035, and $1,250,000,000 of 5.700% Notes due 2055 under an existing shelf registration. All notes were issued under Merck’s longstanding indenture with U.S. Bank Trust National Association, and the filing also attaches officers’ certificates and a legal opinion related to the new series.
Merck & Co., Inc. is offering multiple series of unsecured notes totaling up to $6.0 billion across maturities from 2027 to 2055. The offering includes $500 million of floating rate notes maturing September 15, 2027 and five fixed-rate series: $750 million 3.850% due 2027, $750 million 4.150% due 2030, $1.0 billion 4.550% due 2032, $1.75 billion 4.950% due 2035 and $1.25 billion 5.700% due 2055. The notes are unsecured and will rank pari passu with other unsecured indebtedness and be structurally subordinated to liabilities of subsidiaries; as of June 30, 2025 certain subsidiaries had $5.7 billion of indebtedness and guaranteed $1.0 billion of parent debt. The floating rate notes reference Compounded SOFR and include detailed benchmark transition and replacement provisions; the prospectus warns of SOFR volatility, limited history and potential adverse effects if benchmark replacement occurs. The fixed-rate notes pay semiannual interest and may be optionally redeemed by the issuer under specified Treasury-rate-based formulas. The notes will be issued in book-entry form through DTC.
Merck & Co., Inc. prospectus supplement describes an offering of multiple series of unsecured notes, including floating rate notes tied to Compounded SOFR and several fixed-rate series. The notes will be issued in global, book-entry form through DTC and will not be listed on an exchange; currently there is no public market. The issuer is a finance subsidiary whose obligations will be unsecured and effectively junior to any secured debt and structurally subordinated to non‑guarantor subsidiaries' liabilities. The prospectus details SOFR-related volatility and benchmark transition risks, optional redemption mechanics for fixed-rate series, customary transfer and payment procedures, defeasance features, restrictive covenants (including limits on secured debt and sale-leaseback transactions) and events of default. Several key economic terms (aggregate sizes, exact interest rates, specific maturity dates and settlement dates) are redacted in the provided text.
Merck & Co., Inc. prospectus supplement describes an offering of multiple series of unsecured notes, including floating rate notes tied to Compounded SOFR and several fixed-rate series. The notes will be issued in global, book-entry form through DTC and will not be listed on an exchange; currently there is no public market. The issuer is a finance subsidiary whose obligations will be unsecured and effectively junior to any secured debt and structurally subordinated to non‑guarantor subsidiaries' liabilities. The prospectus details SOFR-related volatility and benchmark transition risks, optional redemption mechanics for fixed-rate series, customary transfer and payment procedures, defeasance features, restrictive covenants (including limits on secured debt and sale-leaseback transactions) and events of default. Several key economic terms (aggregate sizes, exact interest rates, specific maturity dates and settlement dates) are redacted in the provided text.
Merck & Co., Inc. filed a Form 13F reporting its institutional holdings. The Form 13F information table total value is $215,600,331. The report was signed by Kelly Grez, Corporate Secretary on 08-13-2025 and lists Merck Sharp & Dohme LLC as an included manager.